CARISMA Therapeutics Q2 2024 GAAP EPS $(0.27) Beats $(0.32) Estimate, Sales $9.197M Beat $3.925M Estimate
Portfolio Pulse from Benzinga Newsdesk
CARISMA Therapeutics (NASDAQ:CARM) reported Q2 2024 GAAP EPS of $(0.27), beating the estimate of $(0.32). Sales were $9.197M, significantly surpassing the $3.925M estimate. This represents a 44.9% improvement in EPS and a 158.34% increase in sales compared to the same period last year.
August 08, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CARISMA Therapeutics reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.27) beating the $(0.32) estimate and sales of $9.197M surpassing the $3.925M estimate. This indicates strong financial performance and significant year-over-year improvements.
The better-than-expected EPS and sales figures indicate strong financial performance and operational efficiency. The significant year-over-year improvements in both EPS and sales suggest positive momentum for the company, likely leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100